Development of antiviral therapy for severe acute respiratory syndrome.
Identifieur interne : 004866 ( Main/Exploration ); précédent : 004865; suivant : 004867Development of antiviral therapy for severe acute respiratory syndrome.
Auteurs : Jindrich Cinatl [Allemagne] ; Martin Michaelis ; Gerold Hoever ; Wolfgang Preiser ; Hans Wilhelm DoerrSource :
- Antiviral research [ 0166-3542 ] ; 2005.
Descripteurs français
- KwdFr :
- Animaux, Antiviraux (usage thérapeutique), Conception de médicament, Flambées de maladies, Humains, Infections à coronavirus (), Infections à coronavirus (traitement médicamenteux), Infections à coronavirus (transmission), Infections à coronavirus (épidémiologie), Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (traitement médicamenteux), Syndrome respiratoire aigu sévère (transmission), Syndrome respiratoire aigu sévère (épidémiologie), Vaccins antiviraux (immunologie), Virus du SRAS (), Virus du SRAS (immunologie).
- MESH :
- immunologie : Vaccins antiviraux, Virus du SRAS.
- traitement médicamenteux : Infections à coronavirus, Syndrome respiratoire aigu sévère.
- usage thérapeutique : Antiviraux, Infections à coronavirus, Syndrome respiratoire aigu sévère.
- épidémiologie : Infections à coronavirus, Syndrome respiratoire aigu sévère.
- Animaux, Conception de médicament, Flambées de maladies, Humains, Infections à coronavirus, Syndrome respiratoire aigu sévère, Virus du SRAS.
English descriptors
- KwdEn :
- Animals, Antiviral Agents (therapeutic use), Coronavirus Infections (drug therapy), Coronavirus Infections (epidemiology), Coronavirus Infections (prevention & control), Coronavirus Infections (transmission), Disease Outbreaks, Drug Design, Humans, SARS Virus (drug effects), SARS Virus (immunology), Severe Acute Respiratory Syndrome (drug therapy), Severe Acute Respiratory Syndrome (epidemiology), Severe Acute Respiratory Syndrome (prevention & control), Severe Acute Respiratory Syndrome (transmission), Viral Vaccines (immunology).
- MESH :
- chemical , immunology : Viral Vaccines.
- chemical , therapeutic use : Antiviral Agents.
- drug effects : SARS Virus.
- drug therapy : Coronavirus Infections, Severe Acute Respiratory Syndrome.
- epidemiology : Coronavirus Infections, Severe Acute Respiratory Syndrome.
- immunology : SARS Virus.
- prevention & control : Coronavirus Infections, Severe Acute Respiratory Syndrome.
- transmission : Coronavirus Infections, Severe Acute Respiratory Syndrome.
- Animals, Disease Outbreaks, Drug Design, Humans.
Abstract
A new disease, the severe acute respiratory distress syndrome (SARS), caused by the SARS coronavirus (SARS-CoV), emerged at the beginning of 2003 and rapidly spread throughout the world. Although the disease had disappeared in June 2003 its re-emergence cannot be excluded. The development of vaccines against SARS-CoV may take years. Therefore, the availability of effective antiviral drugs against SARS-CoV may be crucial for the control of future SARS outbreaks. In this review, experimental and clinical data about potential anti-SARS drugs is summarised and discussed. Animal model studies will be needed to help to determine which interventions warrant controlled clinical testing.
DOI: 10.1016/j.antiviral.2005.03.002
PubMed: 15878786
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002753
- to stream PubMed, to step Curation: 002753
- to stream PubMed, to step Checkpoint: 002748
- to stream Ncbi, to step Merge: 000F34
- to stream Ncbi, to step Curation: 000F34
- to stream Ncbi, to step Checkpoint: 000F34
- to stream Main, to step Merge: 004B72
- to stream Main, to step Curation: 004866
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Development of antiviral therapy for severe acute respiratory syndrome.</title><author><name sortKey="Cinatl, Jindrich" sort="Cinatl, Jindrich" uniqKey="Cinatl J" first="Jindrich" last="Cinatl">Jindrich Cinatl</name><affiliation wicri:level="3"><nlm:affiliation>Institut für Medizinische Virologie, Klinikum der Johann Wolfgang Goethe-Universität, Paul Ehrlich-Str. 40, 60596 Frankfurt am Main, Germany. Cinatl@em.uni-frankfurt.de</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institut für Medizinische Virologie, Klinikum der Johann Wolfgang Goethe-Universität, Paul Ehrlich-Str. 40, 60596 Frankfurt am Main</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Darmstadt</region><settlement type="city">Francfort-sur-le-Main</settlement></placeName></affiliation></author><author><name sortKey="Michaelis, Martin" sort="Michaelis, Martin" uniqKey="Michaelis M" first="Martin" last="Michaelis">Martin Michaelis</name></author><author><name sortKey="Hoever, Gerold" sort="Hoever, Gerold" uniqKey="Hoever G" first="Gerold" last="Hoever">Gerold Hoever</name></author><author><name sortKey="Preiser, Wolfgang" sort="Preiser, Wolfgang" uniqKey="Preiser W" first="Wolfgang" last="Preiser">Wolfgang Preiser</name></author><author><name sortKey="Doerr, Hans Wilhelm" sort="Doerr, Hans Wilhelm" uniqKey="Doerr H" first="Hans Wilhelm" last="Doerr">Hans Wilhelm Doerr</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:15878786</idno><idno type="pmid">15878786</idno><idno type="doi">10.1016/j.antiviral.2005.03.002</idno><idno type="wicri:Area/PubMed/Corpus">002753</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002753</idno><idno type="wicri:Area/PubMed/Curation">002753</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002753</idno><idno type="wicri:Area/PubMed/Checkpoint">002748</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002748</idno><idno type="wicri:Area/Ncbi/Merge">000F34</idno><idno type="wicri:Area/Ncbi/Curation">000F34</idno><idno type="wicri:Area/Ncbi/Checkpoint">000F34</idno><idno type="wicri:doubleKey">0166-3542:2005:Cinatl J:development:of:antiviral</idno><idno type="wicri:Area/Main/Merge">004B72</idno><idno type="wicri:Area/Main/Curation">004866</idno><idno type="wicri:Area/Main/Exploration">004866</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Development of antiviral therapy for severe acute respiratory syndrome.</title><author><name sortKey="Cinatl, Jindrich" sort="Cinatl, Jindrich" uniqKey="Cinatl J" first="Jindrich" last="Cinatl">Jindrich Cinatl</name><affiliation wicri:level="3"><nlm:affiliation>Institut für Medizinische Virologie, Klinikum der Johann Wolfgang Goethe-Universität, Paul Ehrlich-Str. 40, 60596 Frankfurt am Main, Germany. Cinatl@em.uni-frankfurt.de</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institut für Medizinische Virologie, Klinikum der Johann Wolfgang Goethe-Universität, Paul Ehrlich-Str. 40, 60596 Frankfurt am Main</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Darmstadt</region><settlement type="city">Francfort-sur-le-Main</settlement></placeName></affiliation></author><author><name sortKey="Michaelis, Martin" sort="Michaelis, Martin" uniqKey="Michaelis M" first="Martin" last="Michaelis">Martin Michaelis</name></author><author><name sortKey="Hoever, Gerold" sort="Hoever, Gerold" uniqKey="Hoever G" first="Gerold" last="Hoever">Gerold Hoever</name></author><author><name sortKey="Preiser, Wolfgang" sort="Preiser, Wolfgang" uniqKey="Preiser W" first="Wolfgang" last="Preiser">Wolfgang Preiser</name></author><author><name sortKey="Doerr, Hans Wilhelm" sort="Doerr, Hans Wilhelm" uniqKey="Doerr H" first="Hans Wilhelm" last="Doerr">Hans Wilhelm Doerr</name></author></analytic><series><title level="j">Antiviral research</title><idno type="ISSN">0166-3542</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiviral Agents (therapeutic use)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (epidemiology)</term><term>Coronavirus Infections (prevention & control)</term><term>Coronavirus Infections (transmission)</term><term>Disease Outbreaks</term><term>Drug Design</term><term>Humans</term><term>SARS Virus (drug effects)</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (drug therapy)</term><term>Severe Acute Respiratory Syndrome (epidemiology)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term><term>Severe Acute Respiratory Syndrome (transmission)</term><term>Viral Vaccines (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Antiviraux (usage thérapeutique)</term><term>Conception de médicament</term><term>Flambées de maladies</term><term>Humains</term><term>Infections à coronavirus ()</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Infections à coronavirus (transmission)</term><term>Infections à coronavirus (épidémiologie)</term><term>Syndrome respiratoire aigu sévère ()</term><term>Syndrome respiratoire aigu sévère (traitement médicamenteux)</term><term>Syndrome respiratoire aigu sévère (transmission)</term><term>Syndrome respiratoire aigu sévère (épidémiologie)</term><term>Vaccins antiviraux (immunologie)</term><term>Virus du SRAS ()</term><term>Virus du SRAS (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Vaccins antiviraux</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="transmission" xml:lang="en"><term>Coronavirus Infections</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term><term>Infections à coronavirus</term><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Disease Outbreaks</term><term>Drug Design</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Conception de médicament</term><term>Flambées de maladies</term><term>Humains</term><term>Infections à coronavirus</term><term>Syndrome respiratoire aigu sévère</term><term>Virus du SRAS</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A new disease, the severe acute respiratory distress syndrome (SARS), caused by the SARS coronavirus (SARS-CoV), emerged at the beginning of 2003 and rapidly spread throughout the world. Although the disease had disappeared in June 2003 its re-emergence cannot be excluded. The development of vaccines against SARS-CoV may take years. Therefore, the availability of effective antiviral drugs against SARS-CoV may be crucial for the control of future SARS outbreaks. In this review, experimental and clinical data about potential anti-SARS drugs is summarised and discussed. Animal model studies will be needed to help to determine which interventions warrant controlled clinical testing.</div></front></TEI><affiliations><list><country><li>Allemagne</li></country><region><li>District de Darmstadt</li><li>Hesse (Land)</li></region><settlement><li>Francfort-sur-le-Main</li></settlement></list><tree><noCountry><name sortKey="Doerr, Hans Wilhelm" sort="Doerr, Hans Wilhelm" uniqKey="Doerr H" first="Hans Wilhelm" last="Doerr">Hans Wilhelm Doerr</name><name sortKey="Hoever, Gerold" sort="Hoever, Gerold" uniqKey="Hoever G" first="Gerold" last="Hoever">Gerold Hoever</name><name sortKey="Michaelis, Martin" sort="Michaelis, Martin" uniqKey="Michaelis M" first="Martin" last="Michaelis">Martin Michaelis</name><name sortKey="Preiser, Wolfgang" sort="Preiser, Wolfgang" uniqKey="Preiser W" first="Wolfgang" last="Preiser">Wolfgang Preiser</name></noCountry><country name="Allemagne"><region name="Hesse (Land)"><name sortKey="Cinatl, Jindrich" sort="Cinatl, Jindrich" uniqKey="Cinatl J" first="Jindrich" last="Cinatl">Jindrich Cinatl</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004866 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004866 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:15878786
|texte= Development of antiviral therapy for severe acute respiratory syndrome.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:15878786" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |